GlassScriptPhysician profile
Sumer D Anderson
NPI 1992071559
$8,195.79
in general payments reported to CMS, 2019-2025
28 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $984 · 2022: $1,306 · 2023: $1,609 · 2024: $2,236 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,905.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,690.36 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $989.29 | 2021-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $686.24 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $630.50 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $451.02 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $448.55 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alkermes, INC. | $436.41 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $414.98 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $344.61 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $313.48 | 2023-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $300.57 | 2022-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $223.98 | 2021-2025 | Trintellix |
| Corium, LLC | $212.20 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $168.21 | 2021-2022 | |
| Axsome Therapeutics, INC. | $149.47 | 2022-2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $107.85 | 2023-2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $107.32 | 2022-2024 | |
| Indivior INC. | $106.31 | 2022-2025 | Perseris, Sublocade |
| Idorsia Pharmaceuticals US INC | $85.83 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $79.01 | 2024-2025 | Cobenfy |
| Braeburn INC. | $70.16 | 2024-2025 | Brixadi |
| Lilly USA, LLC | $50.16 | 2022-2024 | Jardiance, Zepbound, Mounjaro |
| Noven Therapeutics, LLC | $48.87 | 2024 | Xelstrym |
| Tempus Ai, INC | $25.86 | 2025 | Xt Cdx |
| Collegium Pharmaceutical, INC. | $15.02 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $14.39 | 2023 | Loreev Xr, Sertraline Hcl |
| Depuy Synthes Sales INC. | $13.71 | 2023 | Tfn-Advance |
| Eisai INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumer Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.